At 25, Ellen Rudolph was supposed to be thriving.

She was living in New York, building her career at one of the most talked about health tech companies in the country. From the outside, everything made sense. She was doing exactly what she was supposed to do.

Then her body stopped cooperating.

The symptoms came on suddenly. Debilitating fatigue. Brain fog. Neurological and cardiac episodes that left her terrified and, at times, unable to function. She went to every specialist she could find. Endocrinologists. Rheumatologists. Cardiologists. Hematologists.

Again and again, she heard the same thing.

Her labs looked normal. There was nothing wrong. Maybe she should see a therapist.

It took two years and $10,000 out of her own pocket to finally understand what was happening.

Lyme disease. Toxic mold exposure. Heavy metal toxicity. Autoimmune markers. A body under strain in ways the system had failed to recognize.

When she began to recover, she made a decision.

This was the problem she would dedicate her life to.

In 2022, she founded WellTheory.

The platform provides personalized, root cause care for people living with autoimmune conditions. More than 50 million Americans fall into this category. Many spend years searching for answers. Most are told their symptoms are not real. 80% are women.

WellTheory combines a specialized care team with AI tools that reduce documentation time by 65%. That time is returned to the patient. To listening. To care that feels present.

In its first eighteen months, the company partnered with Fortune 100 employers and major health plans. Membership has grown tenfold in the past year. Revenue fivefold.

In 2025, WellTheory raised a $14M Series A. Every institutional investor in that round was a female partner. A reflection of both who autoimmune disease affects and the kind of company Ellen chose to build.

She spent years being told nothing was wrong.

She built something to make sure nobody else has to hear that.